MRNA
مرنةTechnical Analysis & Signals
The Merna stock is trading in a narrow range with positive signals that may support continued good performance.
Technical Analysis
The stock shows signs of bullish divergence, indicating the potential for continued upward momentum. The RSI at 62.4 suggests positive momentum.
Support & Resistance Levels
The key support level is at 7.65 SAR, while resistance is at 8.05 SAR. The stock may face challenges in breaking through the current resistance level.
Volume Analysis
Trading volume may be low, indicating a lack of strong pressure from buyers or sellers. This could affect the stock's ability to move significantly.
Fundamental Factors
The stock shows no price-to-earnings (P/E) ratio or dividend yield, indicating a lack of current earnings. This may affect the stock's attractiveness to investors.
Risk Factors
Merna may face risks related to financial and economic stability in the Saudi market. Additionally, the current sideways trend may lead to unexpected volatility.
Recommendation
Disclaimer: This analysis is for educational purposes only and does not constitute investment advice. It is advisable to closely monitor the stock under current conditions.
Financial Fundamentals
Price Data
Price Chart - MRNA
4082Technical Analysis
Moving Averages
Momentum Indicators
Bollinger Bands
Within BandTrend Strength (ADX)
Weak TrendFinancial Summary
Valuation
- Market Cap
- 572.14M
- P/E Ratio
- N/A
- P/B Ratio
- 0.70
- EPS (Earnings/Share)
- -0.10
Profitability
- Revenue
- 103.10M
- Net Income
- -29.89M
- Return on Equity (ROE)
- -4.00%
- Shares Outstanding
- 71.43M
Balance Sheet
- Total Assets
- 1.44B
- Total Debt
- 477.06M
- Debt/Equity
- 0.59
- Free Float %
- N/A
Dividends & Margins
- Dividend Yield
- 0.00%
- Dividend/Share
- 0.00
- Book Value
- 11.44
Financial data extracted from published quarterly reports. All values in SAR unless otherwise stated.
Historical Financial Data
5 years| Year | Revenue | Net Income | Total Assets | Total Debt | EPS |
|---|---|---|---|---|---|
| 2025 | 218.48M +13.0% | 1.01M -96.9% | 1.44B +0.9% | 569.62M +4.9% | 0.01 -97.8% |
| 2024 | 193.41M +14.2% | 32.72M +5.6% | 1.43B +6.4% | 543.12M +17.1% | 0.46 +7.0% |
| 2023 | 169.42M +7.1% | 30.97M -31.2% | 1.34B +9.7% | 463.84M -25.8% | 0.43 -31.7% |
| 2022 | 158.11M | 44.98M | 1.22B | 625.04M | 0.63 |
| 2021 | — | — | — | — | — |
Historical data sourced from Yahoo Finance and may differ from official audited financial reports.
Price Forecast
These forecasts are based on technical analysis and AI and do not constitute investment advice. Past performance does not guarantee future results.
News & Events
No news currently available for MRNA
Dividend History
Dividend data from Tadawul records. All amounts in SAR. Estimated yield calculated based on year-end price.
Risk Assessment
Risk Factors
Average True Range 2.6% of stock price
Trading volume below average
Debt-to-equity ratio 0.59
ADX indicator at 19 — no clear direction
Moderate risk factors with some sector pressures
This assessment is automated based on quantitative data and does not constitute investment advice. Please consult a licensed financial advisor before making investment decisions.
FAQ
1 What is MRNA stock price today?
MRNA (4082) stock price today is 8.01 SAR, declining by -0.50% compared to the previous session close. The 52-week price range is between 7.29 SAR and 11.80 SAR.
2 What is MRNA stock valuation?
The automated analysis signal for MRNA is "Hold" with 65% confidence. The P/B ratio is 0.70.
3 Is MRNA Shariah-compliant?
Yes, MRNA (4082) is Shariah-compliant according to the latest lists approved by relevant Shariah authorities.
4 What are MRNA dividend distributions?
No dividend payment data is currently available for MRNA. The company may not distribute dividends or the data has not been updated yet.
5 What is MRNA weekly performance?
MRNA performance over different time periods: weekly change +3.22%, monthly +3.76%, and year-to-date -17.25%. The stock is currently trading with a volume of 41,656 shares.
6 What is the target level for MRNA?
According to automated analysis for MRNA: Short-term target (1-2 weeks): 8.08 SAR. Support level: 7.65 SAR. Resistance level: 8.05 SAR. Note: These are automated analytical levels and do not constitute investment advice.
Disclaimer
The information provided on this page is for educational and analytical purposes only and does not constitute investment advice or a recommendation to buy or sell. Past performance does not guarantee future results. All investments involve risk including loss of capital. Please consult a licensed financial advisor before making any investment decisions.
Automated analysis relies on historical data and technical indicators and may not reflect future market conditions.